H
Haolin Xu
Researcher at Duke University
Publications - 65
Citations - 1923
Haolin Xu is an academic researcher from Duke University. The author has contributed to research in topics: Medicine & Heart failure. The author has an hindex of 15, co-authored 49 publications receiving 1101 citations. Previous affiliations of Haolin Xu include University of California, Davis & Durham University.
Papers
More filters
Journal ArticleDOI
Heart Failure With Preserved, Borderline, and Reduced Ejection Fraction: 5-Year Outcomes.
Kevin S. Shah,Haolin Xu,Roland A. Matsouaka,Deepak L. Bhatt,Paul A. Heidenreich,Adrian F. Hernandez,Adam D. DeVore,Clyde W. Yancy,Gregg C. Fonarow +8 more
TL;DR: Among patients hospitalized with HF, patients across the EF spectrum have a similarly poor 5-year survival with an elevated risk for cardiovascular and HF admission, which underscores the need to improve treatment of patients with HF.
Journal ArticleDOI
Association of Preceding Antithrombotic Treatment With Acute Ischemic Stroke Severity and In-Hospital Outcomes Among Patients With Atrial Fibrillation.
Ying Xian,Emily C. O'Brien,Li Liang,Haolin Xu,Lee H. Schwamm,Gregg C. Fonarow,Deepak L. Bhatt,Eric E. Smith,DaiWai M. Olson,Lesley Maisch,Deidre Hannah,Brianna Lindholm,Barbara L. Lytle,Michael J. Pencina,Adrian F. Hernandez,Eric D. Peterson +15 more
TL;DR: The prevalence of patients with acute ischemic stroke with known history of AF who were not receiving guideline-recommended antithrombotic treatment before stroke was examined and the association of preceding antithROMbotic therapy with stroke severity and in-hospital outcomes was determined.
Journal ArticleDOI
Temporal trends and factors associated with diabetes mellitus among patients hospitalized with heart failure: Findings from Get With The Guidelines–Heart Failure registry
Justin B. Echouffo-Tcheugui,Haolin Xu,Adam D. DeVore,Phillip J. Schulte,Javed Butler,Clyde W. Yancy,Deepak L. Bhatt,Adrian F. Hernandez,Paul A. Heidenreich,Gregg C. Fonarow +9 more
TL;DR: Temporal trends in diabetes prevalence among patients with HF and in subgroups with reduced ejection fraction, and their relation with quality measures in real-world practice, are assessed between 2005 and 2015.
Journal ArticleDOI
Use of Strategies to Improve Door-to-Needle Times With Tissue-Type Plasminogen Activator in Acute Ischemic Stroke in Clinical Practice: Findings from Target: Stroke.
Ying Xian,Haolin Xu,Barbara L. Lytle,Jason R. Blevins,Eric D. Peterson,Adrian F. Hernandez,Eric E. Smith,Eric E. Smith,Jeffrey L. Saver,Jeffrey L. Saver,Steven R. Messé,Steven R. Messé,Mary Paulsen,Robert E. Suter,Mathew J. Reeves,Edward C. Jauch,Lee H. Schwamm,Gregg C. Fonarow,Gregg C. Fonarow +18 more
TL;DR: A second survey of Get With The Guidelines-Stroke hospitals regarding strategies used to reduce delays after Target: Stroke identified 16 strategies associated with significant reductions in door-to-needle (DTN) times in acute ischemic stroke.
Journal ArticleDOI
Association of 30-Day Readmission Metric for Heart Failure Under the Hospital Readmissions Reduction Program With Quality of Care and Outcomes.
Ambarish Pandey,Harsh Golwala,Haolin Xu,Adam D. DeVore,Roland A. Matsouaka,Michael J. Pencina,Dharam J. Kumbhani,Adrian F. Hernandez,Deepak L. Bhatt,Paul A. Heidenreich,Clyde W. Yancy,James A. de Lemos,Gregg C. Fonarow +12 more
TL;DR: Quality of care and clinical outcomes were comparable among hospitals with high versus low risk-adjusted 30-day HF readmission rates, raising questions about the validity of the HRRP performance metric in identifying and penalizing low-performance centers.